Limits...
Market Access Advancements and Challenges in "Drug-Companion Diagnostic Test" Co-Development in Europe.

Akhmetov I, Ramaswamy R, Akhmetov I, Thimmaraju PK - J Pers Med (2015)

Bottom Line: However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders.This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution.Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.

View Article: PubMed Central - PubMed

Affiliation: Phamax Analytics Resources Pvt. Ltd. #19, KMJ Ascend 1st Cross, 17th C Main 5th Block, Koramangala Bangalore 560 095, India. ildar.akhmetov@phamax.ch.

ABSTRACT
The pharma ecosphere is witnessing a measured transformation from the one-size-fits-all or blockbuster model of drugs to more informed and tailored personalized treatments that facilitate higher safety and efficacy for a relevant sub-population. However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders. This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution. Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.

No MeSH data available.


Related in: MedlinePlus

Growth in health expenditure per capita in select European markets, 2000–2012 (USD PPP). This figure shows an increase in healthcare expenditure per capita (in USD, purchasing power parity) between 2000 and 2012. The growth in healthcare spending signifies the financial pressure on state budgets and a need for novel cost-effective therapeutic solutions [18].
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4493497&req=5

jpm-05-00213-f002: Growth in health expenditure per capita in select European markets, 2000–2012 (USD PPP). This figure shows an increase in healthcare expenditure per capita (in USD, purchasing power parity) between 2000 and 2012. The growth in healthcare spending signifies the financial pressure on state budgets and a need for novel cost-effective therapeutic solutions [18].

Mentions: In countries like Germany, the UK and Sweden, the per-capita expenditure on health has increased by almost 80% since 2000, while in the Netherlands, Poland and Slovakia, this index has grown more than two times (Figure 2) [18]. As a proportion of GDP, healthcare spending has exceeded economic growth in almost all European countries in the past fifteen years.


Market Access Advancements and Challenges in "Drug-Companion Diagnostic Test" Co-Development in Europe.

Akhmetov I, Ramaswamy R, Akhmetov I, Thimmaraju PK - J Pers Med (2015)

Growth in health expenditure per capita in select European markets, 2000–2012 (USD PPP). This figure shows an increase in healthcare expenditure per capita (in USD, purchasing power parity) between 2000 and 2012. The growth in healthcare spending signifies the financial pressure on state budgets and a need for novel cost-effective therapeutic solutions [18].
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4493497&req=5

jpm-05-00213-f002: Growth in health expenditure per capita in select European markets, 2000–2012 (USD PPP). This figure shows an increase in healthcare expenditure per capita (in USD, purchasing power parity) between 2000 and 2012. The growth in healthcare spending signifies the financial pressure on state budgets and a need for novel cost-effective therapeutic solutions [18].
Mentions: In countries like Germany, the UK and Sweden, the per-capita expenditure on health has increased by almost 80% since 2000, while in the Netherlands, Poland and Slovakia, this index has grown more than two times (Figure 2) [18]. As a proportion of GDP, healthcare spending has exceeded economic growth in almost all European countries in the past fifteen years.

Bottom Line: However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders.This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution.Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.

View Article: PubMed Central - PubMed

Affiliation: Phamax Analytics Resources Pvt. Ltd. #19, KMJ Ascend 1st Cross, 17th C Main 5th Block, Koramangala Bangalore 560 095, India. ildar.akhmetov@phamax.ch.

ABSTRACT
The pharma ecosphere is witnessing a measured transformation from the one-size-fits-all or blockbuster model of drugs to more informed and tailored personalized treatments that facilitate higher safety and efficacy for a relevant sub-population. However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders. This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution. Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.

No MeSH data available.


Related in: MedlinePlus